Peptides DB
Research-centric peptide and protocol reference hub
Study 9 of 30Mazdutide (IBI362) literatureHuman vaccines & immunotherapeutics · Observational2026

School nurses' perceptions of providing the HPV vaccine to adolescents in undervaccinated communities in Stockholm: A qualitative study.

School nurses recognize their influence on HPV vaccine uptake but face challenges that hinder their efforts, indicating a need for additional support.

Read at Human vaccines & immunotherapeuticsAdd to compare

Where it sits

this study against the rest of the mazdutide (ibi362) corpus
8
Preclinical
10
Observational · this one
0
Open-label
3
Randomised
9
Reviews

Summary and findings

This qualitative study explored school nurses' perceptions regarding the challenges of providing the HPV vaccine to adolescents in undervaccinated communities in Stockholm. The study involved 21 in-depth interviews conducted between June and November 2024. Key themes identified include the nurses' individual responsibilities, their dual roles in care and public health, and the sensitivity surrounding HPV and sexual health.

How much of this paper we could read: full text read (0.80). We had a clear abstract, so the summary below closely tracks the paper. What this means →
n=212026

Abstract

The authors’ words, as Human vaccines & immunotherapeutics supplied them

In Sweden, HPV vaccination is freely available to all adolescents aged 10-12 through a national, school-based program, but vaccine confidence and uptake are lower than for other childhood vaccines, with notable disparities between groups. School nurses are uniquely positioned to influence this, and the aim of this qualitative study was thus to understand their perceptions about the challenges associated with providing the HPV vaccine to adolescents in undervaccinated communities in Stockholm, Sweden. Between June and November 2024, we conducted 21 in-depth interviews with school nurses working in undervaccinated communities in Stockholm. The data was analyzed using inductive reflexive thematic analysis, which generated three themes: (1) School nurses are left to manage HPV vaccination by themselves; (2) Individual care and public health - the school nurses' dual responsibilities; and (3) Navigating sensitivity around HPV and sex. The themes illustrate how school nurses recognize their ability to influence uptake, but that various challenges, ranging from high workload to normative ideas about sex, hinder them. Our results suggest that ensuring high HPV vaccine uptake largely depends on the efforts of individual school nurses, which ultimately challenges the sustainability of the HPV vaccination program, indicating the need for further support for school nurses with regards to communication materials and strategies to addressing HPV vaccine hesitancy.

Background

The study addresses the issue of low HPV vaccination uptake among adolescents in Sweden, particularly in undervaccinated communities. Previous research has indicated disparities in vaccine confidence compared to other childhood vaccines. Understanding school nurses' perspectives is crucial as they play a key role in influencing vaccination rates.

Methods

This qualitative study utilized in-depth interviews to gather data from school nurses in Stockholm. A total of 21 interviews were conducted between June and November 2024. Thematic analysis was employed to identify key themes from the interviews.

Results

Not reported in abstract.

Interpretation

The findings highlight the significant role of school nurses in managing HPV vaccination efforts, yet they face numerous challenges that may impact the effectiveness of the vaccination program. While the study provides insights into the barriers faced by nurses, the lack of quantitative data limits the ability to assess the overall impact on vaccination rates.

Key findings

  • 21 in-depth interviews conducted with school nurses.
  • Three themes identified: management of HPV vaccination, dual responsibilities of care, and sensitivity around HPV.

Limitations

  • Qualitative study with no quantitative data reported.
  • Small sample size of 21 interviews.
  • Focus on perceptions rather than measurable outcomes.
  • Not applicable for assessing clinical effectiveness.

Elsewhere in the Mazdutide (IBI362) corpus

BEffectiveness of the Dual GLP-1R/GCGR Agonist Mazdutide in GSD IXc: A Case Report.Journal of clinical medicine · 2023 · n=1 · 20.6% reduction in body weight from 85.0 to 67.5 kg after 4 months.HumanAEfficacy and safety of mazdutide in adults with obesity or overweight: a US-based, multicentre, phase 2, randomised, placebo-controlled clinical trial.The lancet. Diabetes & endocrinology · 2025 · n=179 · -18.1% bodyweight change with 16 mg mazdutide at 32 weeks, n=51, p<0.0001.HumanAEfficacy and Safety of Dual GLP-1/Glucagon Receptor Agonism in Overweight and Obesity: A Class-Specific Systematic Review and Meta-Analysis.Diabetes, obesity & metabolism · 2023 · -6.65 kg absolute body weight reduction, MD, moderate certainty.reviewDEfficacy and Safety of Dual GLP-1/Glucagon Receptor Agonism in Overweight and Obesity: A Class-Specific Systematic Review and Meta-Analysis.Diabetes, obesity & metabolism · 2026 · -6.65 kg absolute body weight reduction, MD, moderate certainty.reviewDTreatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity: Research Summary.JAMA · 2026reviewCExternal resistance modulates anodic biofilm architecture, electrochemical performance, and EET-related gene expression in Shewanella oneidensis MR-1 microbial fuel cells.Bioelectrochemistry (Amsterdam, Netherlands) · 2026 · Maximum power density of 130 mW m^-2 at 10 Ω.In vitro